Department of Neurosurgery, Stanford University School of Medicine, Palo Alto, California, USA.
Department of Neurology, Stanford University School of Medicine, Palo Alto, California, USA.
Epilepsia. 2022 Apr;63(4):824-835. doi: 10.1111/epi.17180. Epub 2022 Feb 25.
Antiseizure drug (ASD) therapy can significantly impact quality of life for pediatric patients whose epilepsy remains refractory to medications and who experience neuropsychological side effects manifested by impaired cognitive and social development. Contemporary patterns of ASD reduction after pediatric epilepsy surgery across practice settings in the United States are sparsely reported outside of small series. We assessed timing and durability of ASD reduction after pediatric epilepsy surgery and associated effects on health care utilization.
We performed a retrospective analysis of 376 pediatric patients who underwent resective epilepsy surgery between 2007 and 2016 in the United States using the Truven MarketScan database. Filled ASD prescriptions during the pre- and postoperative periods were compared. Univariate and multivariate analyses identified factors associated with achieving a stable discontinuation of or reduction in number of ASDs. Health care utilization and costs were systematically compared.
One hundred seventy-one patients (45.5%) achieved a >90-day ASD-free period after surgery, and 84 (22.3%) additional patients achieved a stable reduction in number of ASDs. Achieving ASD freedom was more common in patients undergoing total hemispherectomy (n = 21, p = .002), and less common in patients with tuberous sclerosis (p = .003). A higher number of preoperative ASDs was associated with a greater likelihood of achieving ASD reduction postoperatively (hazard ratio [HR]: 1.85, 95% confidence interval [CI]: 1.50-2.28), but was not associated with a significant difference in the likelihood of achieving ASD freedom (0.83, 95% CI: 0.49-1.39). Achieving an ASD-free period was associated with fewer hospital readmissions within the first year after surgery.
Patterns of ASD use and discontinuation after pediatric epilepsy surgery provide an unbiased surgical outcome endpoint extractable from administrative databases, where changes in seizure frequency are not captured. This quantitative measure can augment traditional surgical outcome scales, incorporating a significant clinical parameter associated with improved quality of life.
抗癫痫药物(ASD)治疗可显著改善癫痫药物难治且伴有认知和社会发育受损等神经心理副作用的儿科患者的生活质量。目前美国各医疗实践场所关于儿科癫痫手术后 ASD 减少的当代模式,除了一些小型研究系列外,鲜有报道。我们评估了儿科癫痫手术后 ASD 减少的时机和持久性及其对医疗保健利用的影响。
我们使用 Truven MarketScan 数据库,对 2007 年至 2016 年间在美国接受切除术的 376 例儿科患者进行了回顾性分析。比较了术前和术后期间的 ASD 处方。单变量和多变量分析确定了与实现 ASD 停药或减少数量稳定相关的因素。系统比较了医疗保健利用和成本。
171 例患者(45.5%)术后有 >90 天的 ASD 无药期,84 例患者(22.3%)进一步实现了 ASD 数量的稳定减少。行全脑半球切除术的患者(n=21,p=0.002)更常见达到 ASD 停药,而结节性硬化症患者(p=0.003)较少见。术前 ASD 数量越多,术后 ASD 减少的可能性越大(风险比[HR]:1.85,95%置信区间[CI]:1.50-2.28),但与 ASD 停药的可能性无显著差异(0.83,95%CI:0.49-1.39)。达到 ASD 无药期与术后第一年的住院再入院次数减少相关。
儿科癫痫手术后 ASD 使用和停药模式提供了一种从行政数据库中提取的客观手术结果终点,该模式无法捕捉癫痫发作频率的变化。这种定量测量方法可以补充传统的手术结果量表,纳入与生活质量改善相关的重要临床参数。